| Strategy | Suggested MAXO term(s) | Indication / selection factors | Key outcomes / complications | Real-world implementation notes | Sources |
|---|---|---|---|---|---|
| Immediate primary closure | MAXO: surgical repair; primary closure of abdominal wall defect | Best suited to small omphaloceles or cases without major viscero-abdominal disproportion and without prohibitive cardiopulmonary risk; goal is definitive early closure while avoiding dangerous rise in intra-abdominal pressure | Preferred when feasible, but urgent reduction can precipitate abdominal compartment syndrome with reduced cardiac output, splanchnic hypoperfusion, lactic acidosis, renal failure, intestinal ischemia, and hypoventilation; prognosis strongly influenced by associated anomalies rather than closure alone | Standard neonatal surgical approach in many centers for smaller defects; in the Amsterdam cohort, primary closure was performed in 33/40 (82.5%) omphalocele patients overall, though this cohort included both minor and giant cases (pqac-00000005, pqac-00000011) | (pqac-00000005, pqac-00000011) |
| Staged reduction with silo / delayed primary closure | MAXO: staged surgical closure; silo placement; delayed primary closure | Used when primary closure is unsafe because of large defect, liver herniation, or marked viscero-abdominal disproportion; also used to reduce risk of cardiorespiratory compromise | EUPSA summary of giant omphalocele literature reported early closure strategies used patches more often (44% vs 17% for delayed), with mortality 8% for early closure overall versus delayed subgroups: simple 18%, composite 0%, patch 63%; intervention-related complications include infection, small-bowel obstruction, abdominal compartment syndrome, and rare vascular kinking of portal/hepatic vessels | Widely used conventional option; silastic/synthetic silo allows gradual bedside or OR reductions before fascial closure; literature is heterogeneous and outcomes depend heavily on defect severity and associated anomalies | (pqac-00000001, pqac-00000002, pqac-00000005) |
| Traction-assisted staged closure (fasciotens® Pediatric) | MAXO: traction-assisted closure; staged surgical closure | Consider for giant omphalocele when primary closure is not amenable but early neonatal fascial closure is desired; aims to enlarge abdominal domain and enable tension-less fascial approximation | Prospective multicenter series: 10 giant omphalocele + 6 gastroschisis; complete fascial closure in all; median time to closure 7 days for giant omphalocele (range 4–22); 2 traction-suture tear-outs and 1 skin dehiscence; no SSI, no abdominal compartment syndrome, and no ventral/umbilical hernia after median 12-month follow-up | Requires specialized device, fascial traction sutures/mesh anchoring, and NICU/surgical expertise; practical recommendations include direct fascial exposure and traction around ~30% body weight | (pqac-00000016, pqac-00000018, pqac-00000019, pqac-00000021) |
| Conservative delayed closure / “paint-and-wait” | MAXO: conservative management; topical medication administration; delayed closure | Recommended when anatomical constraints or high surgical risk preclude primary closure, especially giant omphalocele with liver exteriorization and/or pulmonary hypoplasia/pulmonary hypertension | EUPSA recommends paint-and-wait when primary closure is not feasible; common agents include povidone-iodine and silver sulfadiazine, with Manuka honey of emerging interest; consensus on dosing/duration remains unclear; avoids early compartment syndrome risk but requires prolonged epithelialization and later ventral hernia management | Standard non-operative pathway in many centers for severe giant omphaloceles; later definitive ventral hernia repair often needed; literature lacks standardized protocols | (pqac-00000000, pqac-00000001, pqac-00000002, pqac-00000005) |
| Awake graduated compression dressing | MAXO: compression therapy; staged reduction; enteral feeding support | Alternative bedside strategy for exomphalos major when avoiding repeated general anesthesia/ventilation is desirable and sac integrity permits gradual reduction | Case series of 4 neonates: defects 5–7 cm; dressings started days 1–3; average time to full feeds 1 week; only 1 infant required parenteral nutrition; 3 underwent repair at 2–16 weeks, 1 at 1 year; none required patch repair or prolonged ventilation | Applied at bedside in neonatal ward while infants are awake; parents can be trained for dressing changes and some infants discharged home during compression period; facilitates simultaneous early enteral feeding | (pqac-00000023, pqac-00000024, pqac-00000025) |
| Biological mesh for early closure | MAXO: surgical implantation of biological prosthesis; patch repair | Considered when early closure is pursued but native fascial closure is not yet possible; preferred over synthetic material in EUPSA guidance for early repair | EUPSA consensus states early closure favors biological meshes and suggests lower morbidity/mortality than synthetic materials; however, delayed patch closure had the highest mortality in pooled comparisons (63%), likely reflecting the sickest/severest defects | Choice depends on center experience, contamination risk, tissue availability, and defect severity; biologic material may integrate better than synthetic mesh | (pqac-00000001, pqac-00000002) |
| Component separation / native-tissue delayed closure | MAXO: component separation technique; delayed abdominal wall reconstruction | Used for delayed reconstruction after conservative management or staged reduction, particularly when native tissue closure is possible and patch avoidance is desired | EUPSA notes delayed closure appears most effective using native tissues; complications are generally intervention-related and long-term multidisciplinary follow-up is needed; may reduce need for permanent prosthetic material | Often part of later ventral hernia repair after paint-and-wait or delayed management; timing individualized based on growth, respiratory status, and abdominal domain | (pqac-00000001, pqac-00000002) |


*Table: This table summarizes current management options for omphalocele, especially giant omphalocele, with indications, outcomes, complications, and suggested MAXO annotations. It highlights how treatment choice is driven mainly by defect size, viscero-abdominal disproportion, and cardiopulmonary risk.*